| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 04/05/2001 | CA2386079A1 Compounds for the treatment of ischemia |
| 04/05/2001 | CA2386002A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression |
| 04/05/2001 | CA2385887A1 Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors |
| 04/05/2001 | CA2385498A1 Method to enhance healing of sternum after sternotomy |
| 04/05/2001 | CA2385169A1 43 human secreted proteins |
| 04/05/2001 | CA2385001A1 Pharmaceutically active sulfonyl hydrazide derivatives |
| 04/05/2001 | CA2384997A1 Pharmaceutically active sulfonyl amino acid derivatives |
| 04/05/2001 | CA2384662A1 41 human secreted proteins |
| 04/05/2001 | CA2384265A1 Benzodiazepin derivatives, the production and use thereof |
| 04/05/2001 | CA2382892A1 Substituted benzimidazol derivatives, processes for preparing them and their use as pharmaceutical compositions |
| 04/05/2001 | CA2352194A1 Azepinoindole derivatives, the production and use thereof |
| 04/04/2001 | EP1088822A1 Pharmaceutically active sulfonyl hydrazide derivatives |
| 04/04/2001 | EP1088821A1 Pharmaceutically active sulfonamide derivatives |
| 04/04/2001 | EP1088819A2 6-azauracil derivatives as thyroid receptor ligands |
| 04/04/2001 | EP1088815A1 Pharmaceutically active sulfonyl amino acid derivatives |
| 04/04/2001 | EP1088333A1 Compositions and methods for inhibiting bone resorption |
| 04/04/2001 | EP1087978A1 Use of diazepins for preparing medicines for treating pathological conditions or diseases involving one of the growth hormone release inhibiting factor receptors |
| 04/04/2001 | EP1087971A1 PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS |
| 04/04/2001 | EP1087970A1 PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS |
| 04/04/2001 | EP1087951A1 Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
| 04/04/2001 | EP1087946A1 Aryl alkanoylpyridazines |
| 04/04/2001 | EP1087943A1 Therapeutic biaryl derivatives |
| 04/04/2001 | EP1087937A1 Cyclic hydroxamic acids as metalloproteinase inhibitors |
| 04/04/2001 | EP1087764A1 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty |
| 04/04/2001 | EP1087661A1 Il-8 receptor antagonists |
| 04/04/2001 | EP0929216A4 Method of treating post menopausal diseases, including osteoporosis |
| 04/04/2001 | CN1290266A Benzofuran-4-carboxamides and their therapeutical use |
| 04/04/2001 | CN1290260A Hydroxamic and carboxylic acid derivatives |
| 04/04/2001 | CN1290250A Sulfonylamino derivatives which inhibit matrix-degrading metallopr teinases |
| 04/04/2001 | CN1290165A Benzothiazole Protein tyrosine kinase inhibitors |
| 04/04/2001 | CN1289616A Medicine for treating osteoporosis and its preparing process |
| 04/04/2001 | CN1063955C Medicinal liquor for treating suppurative bone infection |
| 04/04/2001 | CN1063945C External compress paste for discapathy |
| 04/03/2001 | US6211368 Hydrolysis of corresponding ester |
| 04/03/2001 | US6211361 Oxidation, reduction of hymenin |
| 04/03/2001 | US6211244 Aromatic amines for complexing calcium |
| 04/03/2001 | US6211210 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use |
| 04/03/2001 | US6211208 2-aminopyridines containing fused ring substituents |
| 04/03/2001 | US6211197 Carboxylic acid or tetrazole derivates; analgesics, antipyretics, and antiinflammatory agents; side effect reduction |
| 04/03/2001 | US6211191 Integrin receptor antagonists |
| 04/03/2001 | US6211169 Stable calcitriol solution for packaging into vials |
| 04/03/2001 | US6210944 Phosphoribosyl transferase from Staphylococcus aureus |
| 03/30/2001 | WO2003042411A2 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease |
| 03/29/2001 | WO2001022092A2 Method to identify compounds which modulate fra-1 expression fils |
| 03/29/2001 | WO2001022090A1 Method for identifying compounds useful in the therapy of bone disorders |
| 03/29/2001 | WO2001021831A1 Method for identifying novel genes involved in the regulation of angiogenesis, study of said genes and use thereof for therapeutic purposes |
| 03/29/2001 | WO2001021812A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | WO2001021793A1 p21Cip1 REMEDIES FOR RHEUMATISM |
| 03/29/2001 | WO2001021658A1 32 human secreted proteins |
| 03/29/2001 | WO2001021643A2 Parathyroid hormone analogues for the treatment of osteoporosis |
| 03/29/2001 | WO2001021628A1 A substantially cell membrane impermeable compound and use thereof |
| 03/29/2001 | WO2001021605A2 Method for extracting compounds of furan lipids and polyhydroxylated fatty alcohols of avocado, composition based on said compounds and use of said compounds in therapy, cosmetics and food |
| 03/29/2001 | WO2001021602A1 Oxa- and thiazole derivatives useful as antidiabetic and antiobesity agents |
| 03/29/2001 | WO2001021600A1 Caspase inhibitor |
| 03/29/2001 | WO2001021598A1 Therapeutic quinazoline compounds |
| 03/29/2001 | WO2001021591A1 Pyrazole derivatives |
| 03/29/2001 | WO2001021587A2 Hydroxyfunctional amide 1h-indole derivatives active as spla2 inhibitors |
| 03/29/2001 | WO2001021584A1 Tyrosine derivatives |
| 03/29/2001 | WO2001021583A1 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient |
| 03/29/2001 | WO2001021213A2 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | WO2001021204A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | WO2001021202A2 Treatment of chronic inflammatory disease by inhibiting sub-groups of activated t-cells |
| 03/29/2001 | WO2001021198A1 Method for reducing the risk of cancer |
| 03/29/2001 | WO2001021186A1 Compositions inhibiting muscle atrophy |
| 03/29/2001 | WO2001021159A2 Pharmaceutical composition of nateglinide and another antidiabetcagent |
| 03/29/2001 | WO2001021008A2 Method for increasing pet activity |
| 03/29/2001 | WO2001007067A3 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 03/29/2001 | WO2001002557A8 Neurotrophic factor receptor |
| 03/29/2001 | WO2000075139A3 Benzothiazinone and benzoxazinone compounds |
| 03/29/2001 | WO2000073294A3 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 03/29/2001 | WO2000059875A3 Novel inhibitors of formation of advanced glycation endproducts (age's) |
| 03/29/2001 | WO2000047583A8 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 03/29/2001 | WO2000037487A8 αvβ6 INTEGRIN INHIBITORS |
| 03/29/2001 | WO1999050282A3 Peptides for the treatment, prophylaxis, diagnosis and monitoring of autoimmune diseases |
| 03/29/2001 | DE19946289A1 Benzodiazepin-Derivate, deren Herstellung und Anwendung Benzodiazepine derivatives, their production and use |
| 03/29/2001 | DE19945810A1 Substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Substituted benzimidazole derivatives, processes for their preparation and their use as medicaments |
| 03/29/2001 | CA2847143A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2805979A1 Inhibition of secretiion from non-neuronal cells |
| 03/29/2001 | CA2385697A1 Method for identifying novel genes involved in the regulation of angiogenesis, study of said genes and use thereof for therapeutic purposes |
| 03/29/2001 | CA2385552A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | CA2385480A1 32 human secreted proteins |
| 03/29/2001 | CA2385447A1 Pyrazole derivatives |
| 03/29/2001 | CA2385377A1 Method to identify compounds useful in the therapy of bone disorders |
| 03/29/2001 | CA2384928A1 Method for identifying compounds useful in the therapy of bone disorders |
| 03/29/2001 | CA2384341A1 Parathyroid hormone analogues for the treatment of osteoporosis |
| 03/29/2001 | CA2383598A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | CA2383574A1 Method for reducing the risk of cancer |
| 03/29/2001 | CA2383470A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2383462A1 Therapeutic methods and compounds |
| 03/28/2001 | EP1087230A1 Method for identifying compounds useful in the therapy of bone disorders |
| 03/28/2001 | EP1086692A2 Estrogen agonists and antagonists for multiple indications |
| 03/28/2001 | EP1086232A1 A vaccine-induced hepatitis b viral strain and uses thereof |
| 03/28/2001 | EP1086225A2 Human tumour-derived polypeptide hormone phosphatonin |
| 03/28/2001 | EP1086137A1 Composition and method for modulating dendritic cell-t cell interaction |
| 03/28/2001 | EP1086131A1 Cyclic somatostatin analogs |
| 03/28/2001 | EP1086129A1 Anti-angiogenic proteins and methods of use thereof |
| 03/28/2001 | EP1086108A1 Heterobicyclic and tricyclic nitric oxide synthase inhibitors |
| 03/28/2001 | EP1086106A1 Furopyridine derivatives and their therapeutical use |
| 03/28/2001 | EP1086098A1 Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists |
| 03/28/2001 | EP1086097A1 Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |